49
Participants
Start Date
September 17, 2021
Primary Completion Date
August 31, 2026
Study Completion Date
December 31, 2026
Cabozantinib
Oral Cabozantinib 40-60 mg daily .every 4 weeks as a cycle
Lanreotide
Lanreotide 120 mg deep SC on day 1 every 4 weeks.every 4 weeks as a cycle
RECRUITING
Changhua Christian Hospital, Changhua
RECRUITING
Chang Gung Medical Foundation, Kaohsiung City
RECRUITING
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
RECRUITING
China Medical University Hospital, Taichung
RECRUITING
Taichung Veterans General Hospital, Taichung
RECRUITING
National Cheng Kung University Hospita, Tainan City
RECRUITING
Mackay Memorial Hospital, Taipei
RECRUITING
National Taiwan University Hospital, Taipei
RECRUITING
Taipei Veterans General Hospital, Taipei
RECRUITING
Tri-Service General Hospital, Taipei
RECRUITING
Chang Gung Medical Foundation, Taoyuan District
National Taiwan University Hospital
OTHER
Taipei Veterans General Hospital, Taiwan
OTHER_GOV
Mackay Memorial Hospital
OTHER
Tri-Service General Hospital
OTHER
Changhua Christian Hospital
OTHER
China Medical University Hospital
OTHER
National Cheng-Kung University Hospital
OTHER
Kaohsiung Medical University Chung-Ho Memorial Hospital
OTHER
Taichung Veterans General Hospital
OTHER
National Health Research Institutes, Taiwan
OTHER